Results 101 to 110 of about 10,623 (204)
Development of Cancer Immunotherapeutics Targeting Complement Regulatory Protein CD55
CD55 is one of the complement regulatory/inhibitory proteins and is over-expressed on a wide range of solid tumours. CD55 is also known to be deposited within tumour stroma and is secreted in an active soluble form, mediated by matrix metalloproteinase ...
Bradley, Richard Grayson
core
CD55/decay accelerating factor is part of the lipopolysaccharide‐induced receptor complex
, 2003 Recently, we described an 80-kDa lipopolysaccharide (LPS)-binding membrane protein to be identical to CD55 [decay accelerating factor (DAF)]. Here, we demonstrate that CD55 is able to contribute to lipopolysaccharide (LPS) signaling.
Nötzel, Corinna +8 more
core +1 more source
Up-regulation of CD55 surface expression on MSC by HCMV US proteins.
, 2013 (A) MSC, MSC-E, MSC-US2, MSC-US3, MSC-US6, and MSC-US11 were analyzed for CD55 surface expression by flow cytometry. Top- Percentage of CD55 positive cells for each MSC population. Bottom- MFI ratio for CD55 expression on different MSC populations.
Christopher D. Porada (162148) +6 more
core +1 more source
Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti‐IFC
, 2002 Background: Antigens of the Cromer blood group system reside on the glycoprotein CD55 (decay-accelerating factor). The Inab phenotype is the null phenotype of this system.
Stelling, Marie-José +23 more
core +1 more source
Modulation of IL-10 production by CD3/CD55 induced Type 1 regulatory (Tr1) T-cells [PDF]
A healthy immune system is maintained in a state of balance between pro-inflammatory and anti-inflammatory cells. The paradigm for T-cell activation requires CD80/86:CD28 engagement resulting in differentiation of CD4+ T-helper cells.
Musarrat, Tajkia
core